Joaquin Mateo received his MD from the University of Barcelona in 2006. After completing his medical training in Oncology at the Catalan Institute of Oncology (Barcelona), he completed postgraduate studies in clinical trial design, with special interest for early-phase clinical trials with companion biomarker development.
He joined the Drug Development Unit at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (London) in 2011 for a two-year fellowship under the mentorship of Prof Johann de Bono and Prof Stan Kaye, working in first-in-man clinical trials of several PARP inhibitors and compounds targeting the PI3K-AKT-mTOR pathway. From 2013, he progressively focused his work towards the design and development of clinical trials for castration-resistant prostate cancer (CRPC).
His main interest is the integration of tumour molecular characterisation data into real-time clinical decision-making for patients through multidisciplinary tumour boards, and has been involved in the set up of molecular tumour boards at the Drug Development Unit and Prostate Cancer Targeted Therapy Unit at The Royal Marsden.
After receiving a joint Medical Research Council & Prostate Cancer UK Fellowship award in 2014, he is currently pursuing a PhD at The Institute of Cancer Research (London); the focus of his research is to better understand the prevalence and clinical relevance of germline and somatic DNA repair defects in the progression of prostate cancer and how to therapeutically exploit these aberrations. In 2016, he received a Prostate Cancer Foundation Young Investigator Award to continue working in the development of PARP inhibitors, platinum-based therapies and companion predictive biomarkers for CRPC patients.